Two independent studies linked SARS‑CoV‑2 mRNA vaccines to enhanced antitumor immunity. A Nature report showed that spike‑encoding RNA‑LNPs can remodel the tumor microenvironment and sensitize tumors to checkpoint blockade in preclinical models. Complementary clinical analyses from University of Florida and MD Anderson found that cancer patients who received mRNA COVID‑19 vaccines within 100 days of starting immune‑checkpoint inhibitors had markedly improved three‑year survival versus unvaccinated peers. The work raises potential cross‑benefit hypotheses for mRNA platforms and cancer immunotherapy sequencing.